Companies / IGC Pharma, Inc.

IGC Pharma, Inc.

NYSE: IGCCIK 1326205POTOMAC, MD

Financials · FY2025

Revenue$869.0K
Net income$-4.15M
Total debt$134.0K
Cash$207.0K
Diluted EPS$-0.05
Shares outstanding100.1M

Ownership

100.1M shares outstanding · as of Apr 27, 2026
9.7%Insiders
Ownership
Insiders9.70%9,709,539
Institutions4.55%4,554,175
Public float85.75%85,827,603

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Mukunda RamCEOCEO · Director
5.55%5,559,839
Prins Richard KDirector
1.54%1,541,251
Grimaldi ClaudiaPFO · Director
1.37%1,372,714
Moran James PDirector
1.23%1,235,735

Institutional holders 30

View all →
HolderValue% of shares
Vanguard Group Inc$322.9K1.15%
Geode Capital Management, LLC$274.4K1.04%
BlackRock, Inc.$191.4K0.70%
Renaissance Technologies LLC$127.3K0.48%
Citadel Advisors LLC$78.1K0.28%
State Street Corporation$54.6K0.20%
Susquehanna International Group, LLP$43.6K0.15%
Northern Trust Corp$31.9K0.11%
Lawood & Co$21.1K0.07%
The Goldman Sachs Group, Inc.$18.4K0.07%

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Renaissance Technologies LLC
13F manager
TrimCommon Stock$-114.6K-436K
-47.37%
483,975
0.48% of shares
low
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon Stock$48.1K+183K
+21.26%
1,043,384
1.04% of shares
low
Q1 2026
as of
Dearborn Partners LLC
13F manager
TrimCommon Stock$-6.6K-25K
-29.62%
59,401
0.06% of shares
low
Q4 2025
as of
Bank of America Corp /De
13F manager
TrimCommon Stock$-604-2K
-54.32%
1,808
<0.01% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
IGCCommon StockEquity45408X308BBG000NSSLY8